| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,674,000 |
| Market
Cap: |
72.81(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2298 - $2.97 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 9.4 |
| Insider 3/6 Months : 10 |
|
| Guru Rank Number : 707 |
| Guru Rank Value : 1.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
816,825 |
816,825 |
816,825 |
| Total Buy Value |
$0 |
$194,885 |
$194,885 |
$194,885 |
| Total People Bought |
0 |
3 |
3 |
3 |
| Total Buy Transactions |
0 |
4 |
4 |
4 |
| Total Shares Sold |
56,192 |
121,276 |
273,751 |
412,845 |
| Total Sell Value |
$40,460 |
$65,778 |
$342,884 |
$1,024,948 |
| Total People Sold |
5 |
6 |
7 |
9 |
| Total Sell Transactions |
5 |
11 |
22 |
41 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Joshi Manher |
EVP, Chief Medical Officer |
• • – |
2023-08-16 |
4 |
S |
$1.65 |
$11,526 |
D/D |
(6,975) |
183,571 |
|
68% |
|
| Henrich Jill |
EVP, Global Head RA & Quality |
• • – |
2023-08-16 |
4 |
S |
$1.65 |
$5,531 |
D/D |
(3,346) |
107,691 |
|
68% |
|
| Murugan Amar |
EVP, Chief Legal Officer |
• • – |
2023-08-16 |
4 |
S |
$1.65 |
$14,330 |
D/D |
(8,672) |
265,391 |
|
68% |
|
| Touchon Pascal |
President and CEO |
• • – |
2023-08-16 |
4 |
S |
$1.65 |
$50,835 |
D/D |
(30,766) |
675,905 |
|
68% |
|
| Nguyen Anhco |
EVP, Chief Sci. & Tech Officer |
• • – |
2023-08-16 |
4 |
S |
$1.65 |
$24,997 |
D/D |
(15,126) |
285,999 |
|
68% |
|
| Hyllengren Eric J |
SVP, CFO |
• • – |
2023-08-16 |
4 |
S |
$1.65 |
$13,527 |
D/D |
(8,186) |
217,956 |
|
68% |
|
| Touchon Pascal |
President and CEO |
• • – |
2023-06-27 |
4 |
S |
$1.66 |
$23,723 |
D/D |
(14,291) |
706,671 |
|
30% |
|
| Nguyen Anhco |
EVP, Chief Sci. & Tech Officer |
• – – |
2023-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
301,125 |
|
16% |
|
| Henrich Jill |
EVP, Global Head RA & Quality |
• – – |
2023-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
111,037 |
|
16% |
|
| Joshi Manher |
EVP, Chief Medical Officer |
• – – |
2023-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
190,546 |
|
16% |
|
| Dobmeier Eric |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
116,500 |
|
- |
|
| Seidenberg Beth C |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
115,689 |
|
- |
|
| Mallik Ameet |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
77,500 |
|
- |
|
| Roncarolo Maria Grazia |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
88,500 |
|
- |
|
| Gallagher Carol Giltner |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
189,418 |
|
- |
|
| Heiden William K |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
109,000 |
|
- |
|
| Fust Matthew K |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
109,000 |
|
- |
|
| Touchon Pascal |
President and CEO |
• • – |
2023-05-16 |
4 |
S |
$2.04 |
$60,633 |
D/D |
(29,766) |
720,962 |
|
22% |
|
| Murugan Amar |
EVP, Chief Legal Officer |
• • – |
2023-05-16 |
4 |
S |
$2.04 |
$17,089 |
D/D |
(8,389) |
270,945 |
|
22% |
|
| Hyllengren Eric J |
SVP, CFO |
• • – |
2023-05-16 |
4 |
S |
$2.04 |
$16,131 |
D/D |
(7,918) |
226,142 |
|
22% |
|
| Banard Charlene A. |
EVP, Chief Technical Officer |
• • – |
2023-05-16 |
4 |
S |
$2.04 |
$38,784 |
D/D |
(19,040) |
276,010 |
|
22% |
|
| Hyllengren Eric J |
SVP, CFO |
• – – |
2023-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
234,060 |
|
-29% |
|
| Murugan Amar |
SVP, GC & Secretary |
• – – |
2023-03-02 |
4 |
AS |
$3.63 |
$15,310 |
D/D |
(4,221) |
279,334 |
|
-42% |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
AS |
$3.63 |
$24,921 |
D/D |
(6,871) |
181,978 |
|
-42% |
|
| Dupont Jakob |
EVP, Head of R&D |
• – – |
2023-03-02 |
4 |
AS |
$3.63 |
$18,403 |
D/D |
(5,074) |
290,794 |
|
-42% |
|
731 Records found
|
|
Page 2 of 30 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (3.03%) 
